Thermo Fisher Scientific (TMO) Projected to Announce Quarterly Earnings on Thursday

Thermo Fisher Scientific (NYSE:TMO) will likely be releasing its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect Thermo Fisher Scientific to announce earnings of $5.71 per share and revenue of $11.7060 billion for the quarter. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:30 AM ET.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the prior year, the company posted $5.15 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, analysts expect Thermo Fisher Scientific to post $25 EPS for the current fiscal year and $27 EPS for the next fiscal year.

Thermo Fisher Scientific Trading Down 0.7%

Shares of TMO stock opened at $522.68 on Wednesday. Thermo Fisher Scientific has a 1 year low of $405.15 and a 1 year high of $643.99. The firm has a market capitalization of $194.24 billion, a PE ratio of 28.73, a price-to-earnings-growth ratio of 2.33 and a beta of 0.87. The stock has a fifty day moving average of $487.32 and a two-hundred day moving average of $513.58. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Finally, Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $602.14.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors and hedge funds have recently added to or reduced their stakes in TMO. JPL Wealth Management LLC purchased a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at $28,000. Birchwood Financial Partners Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $29,000. Osterweis Capital Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 151.4% in the 3rd quarter. Osterweis Capital Management Inc. now owns 88 shares of the medical research company’s stock valued at $43,000 after purchasing an additional 53 shares during the period. Finally, Wealth Watch Advisors INC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $44,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.